Catalyst Dossier · compiled by CeliA 🧫
Novo Nordisk A/S (NVO)
Pharmaceutical Preparations · market cap $203.2B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-31 (est.)
NDA Filing
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Novo Nordisk A/S (NVO) is a Danish pharmaceutical giant with ~68,800 employees and a $203B market cap, controlling positions in diabetes, obesity, cardiovascular, and rare disease. The stock trades at ~$49.48, well below the analyst consensus target of ~$47.66 (mean) to $63.06 (high), with a broad pipeline featuring multiple Phase 3 readouts across 2026–2027, headlined by CagriSema, Cagrilintide, and a Phase 3 ATTR-CM program (NNC6019-0001).
The catalyst path
- 2026-12-31 (est.)NDA Filing · Etavopivatimp 8/10
- 2027-01-14 (est.)Phase 2 · UBT251imp 7/10
- 2027-04-01 (est.)Otherimp 6/10
- 2027-05-12 (est.)Phase 3 · Cagrilintideimp 9/10
- 2027-05-16 (est.)Phase 2 · CDR132Limp 7/10
- 2027-08-27 (est.)Phase 3 · Etavopivatimp 9/10
- 2027-09-01 (est.)Phase 3 · Cagrilintideimp 9/10
- 2027-09-03 (est.)Phase 2 · NNC0662-0419imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| NNC6019-0001 | Phase 3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) |
| Semaglutide 1.0 mg | Phase 3 | Obesity |
| CDR132L | Phase 2 | Heart Failure |
| biphasic insulin aspart | Phase 3 | Diabetes |
| NNC109-0012 | Phase 2 | Inflammation |
| Cagrilintide | Phase 3 | Obesity or Overweight |
| Concizumab | Phase 3 | Congenital Bleeding Disorder |
| biphasic human insulin | Phase 3 | Diabetes |
| Insulin Icodec | Phase 3 | Diabetes Mellitus, Type 2 |
| Semaglutide (administered by PDS290 pen) | Phase 2 | Healthy Volunteers Diabetes Mellitus, Type 2 |
| human insulin | Phase 3 | Diabetes |
| insulin 338 (GIPET I) | Phase 2 | Diabetes |
| insulin NPH | Phase 3 | Diabetes |
| NNC0662-0419 | Phase 2 | Overweight |
| turoctocog alfa pegol | Phase 3 | Congenital Bleeding Disorder |
| rosiglitazone | Phase 3 | Diabetes |
| biphasic insulin aspart 50 | Phase 3 | Diabetes |
| DPP-4 inhibitor | Phase 3 | Diabetes |
| NNC0365-3769 (Mim8) | Phase 3 | Haemophilia A |
| Insulin Glargine 100U/mL | Phase 3 | Diabetes Mellitus, Type 2 |
Price & technical context
3-month
-0.8%
6-month
+15.3%
12-month
-24.5%
52-wk range
$35.29–$63.98
vs 50-day MA
-8.1%
vs 200-day MA
-6.5%
Realized vol
46.8%
Max drawdown
-74.6%
Daily closes through 2026-09-17. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NVO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.